Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: TYK2

Gene summary for TYK2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

TYK2

Gene ID

7297

Gene nametyrosine kinase 2
Gene AliasIMD35
Cytomap19p13.2
Gene Typeprotein-coding
GO ID

GO:0002376

UniProtAcc

A0A024R7E4


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
7297TYK2HTA11_3410_2000001011HumanColorectumAD5.91e-039.92e-020.0155
7297TYK2HTA11_2487_2000001011HumanColorectumSER1.38e-032.09e-01-0.1808
7297TYK2HTA11_347_2000001011HumanColorectumAD1.01e-072.68e-01-0.1954
7297TYK2HTA11_411_2000001011HumanColorectumSER9.16e-056.54e-01-0.2602
7297TYK2HTA11_696_2000001011HumanColorectumAD1.58e-073.23e-01-0.1464
7297TYK2HTA11_866_2000001011HumanColorectumAD3.30e-022.54e-01-0.1001
7297TYK2HTA11_1391_2000001011HumanColorectumAD9.74e-103.87e-01-0.059
7297TYK2HTA11_546_2000001011HumanColorectumAD1.65e-022.81e-01-0.0842
7297TYK2HTA11_866_3004761011HumanColorectumAD3.19e-032.18e-010.096
7297TYK2HTA11_10623_2000001011HumanColorectumAD5.79e-032.40e-01-0.0177
7297TYK2HTA11_7696_3000711011HumanColorectumAD1.66e-094.02e-010.0674
7297TYK2HCC1_MengHumanLiverHCC2.57e-371.79e-020.0246
7297TYK2HCC2_MengHumanLiverHCC7.13e-086.16e-030.0107
7297TYK2HCC2HumanLiverHCC2.66e-042.97e+000.5341
7297TYK2S016HumanLiverHCC4.13e-021.62e-010.2243
7297TYK2S027HumanLiverHCC2.53e-035.05e-010.2446
7297TYK2S028HumanLiverHCC8.24e-063.15e-010.2503
7297TYK2S029HumanLiverHCC6.37e-134.99e-010.2581
7297TYK2C04HumanOral cavityOSCC1.33e-073.67e-010.2633
7297TYK2C21HumanOral cavityOSCC3.01e-134.06e-010.2678
Page: 1 2 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0034340ColorectumADresponse to type I interferon22/391858/187232.23e-031.75e-0222
GO:0060337ColorectumADtype I interferon signaling pathway19/391850/187234.23e-032.91e-0219
GO:0071357ColorectumADcellular response to type I interferon19/391852/187236.92e-034.26e-0219
GO:00343401ColorectumSERresponse to type I interferon17/289758/187235.50e-034.07e-0217
GO:003434011LiverHCCresponse to type I interferon43/795858/187239.93e-071.50e-0543
GO:006033711LiverHCCtype I interferon signaling pathway37/795850/187236.13e-067.52e-0537
GO:007135711LiverHCCcellular response to type I interferon38/795852/187237.59e-068.98e-0538
GO:00343405Oral cavityOSCCresponse to type I interferon46/730558/187234.17e-101.11e-0846
GO:00603374Oral cavityOSCCtype I interferon signaling pathway41/730550/187235.59e-101.46e-0841
GO:00713574Oral cavityOSCCcellular response to type I interferon42/730552/187238.50e-102.13e-0842
GO:00192214Oral cavityOSCCcytokine-mediated signaling pathway222/7305472/187232.02e-041.35e-03222
GO:00182123Oral cavityOSCCpeptidyl-tyrosine modification180/7305378/187233.63e-042.22e-03180
GO:00181083Oral cavityOSCCpeptidyl-tyrosine phosphorylation177/7305375/187236.86e-043.83e-03177
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05171ColorectumADCoronavirus disease - COVID-19113/2092232/84659.90e-162.55e-141.63e-14113
hsa05160ColorectumADHepatitis C54/2092157/84653.87e-031.96e-021.25e-0254
hsa051711ColorectumADCoronavirus disease - COVID-19113/2092232/84659.90e-162.55e-141.63e-14113
hsa051601ColorectumADHepatitis C54/2092157/84653.87e-031.96e-021.25e-0254
hsa051712ColorectumSERCoronavirus disease - COVID-1998/1580232/84653.33e-178.50e-166.17e-1698
hsa04217ColorectumSERNecroptosis47/1580159/84655.21e-044.44e-033.22e-0347
hsa051713ColorectumSERCoronavirus disease - COVID-1998/1580232/84653.33e-178.50e-166.17e-1698
hsa042171ColorectumSERNecroptosis47/1580159/84655.21e-044.44e-033.22e-0347
hsa0517142LiverHCCCoronavirus disease - COVID-19167/4020232/84651.50e-144.19e-132.33e-13167
hsa0516921LiverHCCEpstein-Barr virus infection128/4020202/84653.17e-062.79e-051.55e-05128
hsa051652LiverHCCHuman papillomavirus infection188/4020331/84653.34e-041.49e-038.29e-04188
hsa0514521LiverHCCToxoplasmosis70/4020112/84659.25e-043.52e-031.96e-0370
hsa0516021LiverHCCHepatitis C94/4020157/84651.11e-034.10e-032.28e-0394
hsa0516421LiverHCCInfluenza A101/4020171/84651.41e-035.07e-032.82e-03101
hsa0516721LiverHCCKaposi sarcoma-associated herpesvirus infection111/4020194/84653.78e-031.16e-026.45e-03111
hsa051612LiverHCCHepatitis B91/4020162/84651.56e-023.76e-022.09e-0291
hsa0517152LiverHCCCoronavirus disease - COVID-19167/4020232/84651.50e-144.19e-132.33e-13167
hsa0516931LiverHCCEpstein-Barr virus infection128/4020202/84653.17e-062.79e-051.55e-05128
hsa051653LiverHCCHuman papillomavirus infection188/4020331/84653.34e-041.49e-038.29e-04188
hsa0514531LiverHCCToxoplasmosis70/4020112/84659.25e-043.52e-031.96e-0370
Page: 1 2 3 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
TYK2SNVMissense_Mutationc.1327N>Gp.Leu443Valp.L443VP29597protein_codingtolerated(0.91)benign(0.052)TCGA-A8-A08L-01Breastbreast invasive carcinomaFemale>=65III/IVUnknownUnknownSD
TYK2SNVMissense_Mutationc.3157N>Ap.Glu1053Lysp.E1053KP29597protein_codingtolerated(0.28)possibly_damaging(0.496)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
TYK2SNVMissense_Mutationnovelc.3055T>Cp.Tyr1019Hisp.Y1019HP29597protein_codingdeleterious(0.02)probably_damaging(0.994)TCGA-AO-A128-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
TYK2SNVMissense_Mutationnovelc.274N>Ap.Glu92Lysp.E92KP29597protein_codingtolerated(0.74)benign(0.011)TCGA-BH-A0HX-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapyadrimycinSD
TYK2SNVMissense_Mutationc.1309N>Ap.Glu437Lysp.E437KP29597protein_codingdeleterious(0)possibly_damaging(0.641)TCGA-BH-A1EO-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
TYK2SNVMissense_Mutationrs756802293c.2531N>Cp.Leu844Prop.L844PP29597protein_codingdeleterious(0)probably_damaging(0.981)TCGA-C8-A1HO-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapy5-fluorouracilCR
TYK2insertionIn_Frame_Insnovelc.2267_2268insCCCp.Lys756delinsAsnProp.K756delinsNPP29597protein_codingTCGA-A2-A0CP-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanSD
TYK2insertionFrame_Shift_Insnovelc.1114_1115insTGGTGATTTTCATGGGACTGTGTGTTp.Pro372LeufsTer26p.P372Lfs*26P29597protein_codingTCGA-A2-A0CT-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycytoxanSD
TYK2SNVMissense_Mutationc.345N>Ap.Met115Ilep.M115IP29597protein_codingtolerated(0.06)benign(0.045)TCGA-C5-A1BJ-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
TYK2SNVMissense_Mutationnovelc.2554N>Ap.Glu852Lysp.E852KP29597protein_codingdeleterious(0.04)possibly_damaging(0.593)TCGA-C5-A1BK-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 7 8 9 10 11 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitor178102342FEDRATINIB
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitor315661321UPADACITINIB
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEPMID27774822-Compound-Figure9Example15
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEPyrrolo-pyridone derivative 3
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitorCHEMBL2103743TOFACITINIB CITRATE
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitor405067336
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitor385612218
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEAminopyrimidine derivative 5
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEinhibitor178102315RUXOLITINIB
7297TYK2KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, ENZYMEPMID27774822-Compound-Figure3CompoundI-165
Page: 1 2 3 4 5 6 7 8 9